Bausch + Lomb Balance Sheet Health
Financial Health criteria checks 1/6
Bausch + Lomb has a total shareholder equity of $6.7B and total debt of $4.6B, which brings its debt-to-equity ratio to 68.1%. Its total assets and total liabilities are $13.3B and $6.6B respectively. Bausch + Lomb's EBIT is $212.0M making its interest coverage ratio 0.7. It has cash and short-term investments of $315.0M.
Key information
68.1%
Debt to equity ratio
US$4.58b
Debt
| Interest coverage ratio | 0.7x |
| Cash | US$315.00m |
| Equity | US$6.73b |
| Total liabilities | US$6.56b |
| Total assets | US$13.29b |
Recent financial health updates
Recent updates
Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner
May 24Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 30
Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?
Mar 25Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)
Feb 19Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound
Jan 31Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price
Jan 14Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)
Nov 08Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S
Nov 03An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued
Aug 15Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease
Aug 09These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong
May 09Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate
Mar 28Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M
Feb 22Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne
Feb 01Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect
Jan 24Bausch + Lomb acquires AcuFocus for cataract lens
Jan 17Bausch + Lomb says Joseph Papa to serve as CEO until at least March next year
Dec 22Bausch + Lomb stock rises on FDA nod for contact lens rehydrating drops
Dec 13Bausch + Lomb: A Solid Play In Challenging Economic Times
Nov 09Bausch + Lomb reports Q3 mixed earnings; narrows FY22 guidance range
Nov 02Financial Position Analysis
Short Term Liabilities: BLCO's short term assets ($2.7B) exceed its short term liabilities ($1.6B).
Long Term Liabilities: BLCO's short term assets ($2.7B) do not cover its long term liabilities ($4.9B).
Debt to Equity History and Analysis
Debt Level: BLCO's net debt to equity ratio (63.4%) is considered high.
Reducing Debt: Insufficient data to determine if BLCO's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: BLCO's debt is not well covered by operating cash flow (1.7%).
Interest Coverage: BLCO's interest payments on its debt are not well covered by EBIT (0.7x coverage).